Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications

Toxicologic Pathology - Tập 31 Số 1_suppl - Trang 119-122 - 2003
Cindy Farman1, Doug Kornbrust2
1Sierra Biomedical, a Division of Charles River Sparks, Nevada, [email protected]
2Sierra Biomedical, a Division of Charles River Sparks, Nevada

Tóm tắt

Antisense oligodeoxynucleotide compounds (AS ODN) are being developed as therapeutics for various disease indications. Their safety and pharmacokinetics are most commonly evaluated in rodents and nonhuman primates. Traditional AS ODN are short, single strands of DNA, and they target specific mRNA sequences. Plasma clearance of AS ODN is rapid, broad tissue distribution occurs, and elimination is by nuclease metabolism. Structural modifications to AS ODN have been made to enhance their efficacy and improve their safety. A number of class effects are observed with AS ODN that are unrelated to the specific targeted mRNA sequence. Acute effects include activation of the alternative complement pathway and inhibition of the intrinsic coagulation pathway. In monkeys, rodents, and dogs given repeated doses of AS ODN, accumulation of AS ODN and/or metabolites occurs in the form of basophilic granules in various tissues, including the kidney, lymph nodes and liver. A new potential therapeutic application of ODN is that of immune stimulation. Immunostimulatory ODN (IS ODN) are being investigated for use in treating cancer, infectious disease, and allergy. For the development of both AS and IS ODN, primates will continue to be important for safety assessment.

Từ khóa


Tài liệu tham khảo

10.4049/jimmunol.167.9.4878

10.1046/j.1365-2567.2002.01410.x

2001, Curr Opin Investig Drugs, 2, 1444

1997, J Pharmacol Exp Ther, 281, 810

10.1089/oli.1.1997.7.473

10.1016/S0167-4781(99)00147-5

10.1146/annurev.immunol.20.100301.064842

10.1177/019262339902700306

10.1177/019262339902700103

1997, Anticancer Drug Des, 12, 421

2001, J Pharmacol Exp Ther, 298, 1185

10.1182/blood.V92.5.1617

10.1016/S0140-6736(01)05629-X

Thông tin
Thông tin xuất bản

Toxicologic Pathology

Tập 31 Số 1_suppl

119-122

Thông tin tác giả